| |
|
|
|
Attributable to holders of the parent |
|
|
|
|
|
|
|
| |
|
Share
capital
R’000 |
|
Share
premium
R’000 |
|
Non-
distri-
butable
reserves
R’000 |
|
Retained
income
R’000 |
|
Total
attributable
ordinary
shareholders
R’000 |
|
Non-
controlling
interest
R’000 |
|
Total
R’000 |
|
| |
Balance at 30 September 2010 (audited) |
17 365 |
|
1 190 290 |
|
349 061 |
|
1 357 939 |
|
2 914 655 |
|
158 685 |
|
3 073 340 |
|
| |
Share issue |
4 |
|
465 |
|
|
|
|
|
469 |
|
|
|
469 |
|
| |
Movement in treasury shares |
(471) |
|
(272 158) |
|
|
|
|
|
(272 629) |
|
|
|
(272 629) |
|
| |
Share-based payment expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
– continuing operations |
|
|
|
|
3 185 |
|
|
|
3 185 |
|
|
|
3 185 |
|
| |
– discontinued operation |
|
|
|
|
(831) |
|
|
|
(831) |
|
|
|
(831) |
|
| |
Subsequent acquisition of non-controlling interests in: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
– Ayrton Drug Manufacturing Limited |
|
|
|
|
|
|
42 |
|
42 |
|
(69) |
|
(27) |
|
| |
– Addclin Research (Pty) Limited |
|
|
|
|
|
|
1 345 |
|
1 345 |
|
(1 345) |
|
|
|
| |
Disposal of business |
|
|
|
|
|
|
|
|
|
|
(12 644) |
|
(12 644) |
|
| |
Total comprehensive income |
|
|
|
|
(19 209) |
|
353 361 |
|
334 152 |
|
6 915 |
|
341 067 |
|
| |
Profit for the period |
|
|
|
|
|
|
353 361 |
|
353 361 |
|
6 915 |
|
360 276 |
|
| |
Other comprehensive income |
|
|
|
|
(19 209) |
|
|
|
(19 209) |
|
|
|
(19 209) |
|
| |
Dividends |
|
|
|
|
|
|
(177 157) |
|
(177 157) |
|
(21 045) |
|
(198 202) |
|
| |
Balance at 31 March 2011 (unaudited) |
16 898 |
|
918 597 |
|
332 206 |
|
1 535 530 |
|
2 803 231 |
|
130 497 |
|
2 933 728 |
|
| |
Share issue |
21 |
|
2 903 |
|
|
|
|
|
2 924 |
|
|
|
2 924 |
|
| |
Movement in treasury shares |
(31) |
|
(19 269) |
|
|
|
|
|
(19 300) |
|
|
|
(19 300) |
|
| |
Share-based payment expense |
|
|
|
|
3 500 |
|
|
|
3 500 |
|
|
|
3 500 |
|
| |
Acquisition through business combination |
|
|
|
|
|
|
|
|
|
|
14 072 |
|
14 072 |
|
| |
Subsequent acquisition of non-controlling interests in Ayrton Drug Manufacturing Limited |
|
|
|
|
|
|
(4 162) |
|
(4 162) |
|
(5 156) |
|
(9 318) |
|
| |
Total comprehensive income |
|
|
|
|
35 662 |
|
400 844 |
|
436 506 |
|
4 818 |
|
441 324 |
|
| |
Profit for the period |
|
|
|
|
|
|
400 844 |
|
400 844 |
|
3 680 |
|
404 524 |
|
| |
Other comprehensive income |
|
|
|
|
35 662 |
|
|
|
35 662 |
|
1 138 |
|
36 800 |
|
| |
Dividends |
|
|
|
|
|
|
|
|
|
|
(6 607) |
|
(6 607) |
|
| |
Distribution out of share premium |
|
|
(136 943) |
|
|
|
|
|
(136 943) |
|
|
|
(136 943) |
|
|
|
| |
Balance at 30 September 2011 (audited) |
16 888 |
|
765 288 |
|
371 368 |
|
1 932 212 |
|
3 085 756 |
|
137 624 |
|
3 223 380 |
|
| |
Share issue |
45 |
|
5 031 |
|
|
|
|
|
5 076 |
|
|
|
5 076 |
|
| |
Movement in treasury shares |
(41) |
|
(25 509) |
|
|
|
|
|
(25 550) |
|
|
|
(25 550) |
|
| |
Share-based payment expense |
|
|
|
|
9 069 |
|
|
|
9 069 |
|
|
|
9 069 |
|
| |
Subsequent acquisition of non-controlling interests in Ayrton Drug Manufacturing Limited |
|
|
|
|
|
|
(2 000) |
|
(2 000) |
|
(8 752) |
|
(10 752) |
|
| |
Total comprehensive income |
|
|
|
|
(42 050) |
|
335 296 |
|
293 246 |
|
3 342 |
|
296 588 |
|
| |
Profit for the period |
|
|
|
|
|
|
335 296 |
|
335 296 |
|
6 427 |
|
341 723 |
|
| |
Other comprehensive income |
|
|
|
|
(42 050) |
|
|
|
(42 050) |
|
(3 085) |
|
(45 135) |
|
| |
Dividends |
|
|
|
|
|
|
|
|
|
|
(1 280) |
|
(1 280) |
|
| |
Distribution out of share premium |
|
|
(183 831) |
|
|
|
|
|
(183 831) |
|
|
|
(183 831) |
|
| |
Balance at 31 March 2012 (unaudited) |
16 892 |
|
560 979 |
|
338 387 |
|
2 265 508 |
|
3 181 766 |
|
130 934 |
|
3 312 700 |
|
|
|
